Antisense Oligonucleotide Compositions for Ataxin 2 Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective treatments for neurodegenerative diseases such as spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism, which are associated with Ataxin 2 protein expression and toxicity.
Innovation Solution
The use of antisense compounds, particularly modified oligonucleotides, to modulate Ataxin 2 mRNA and protein expression, reducing their levels in a time- and dose-dependent manner, thereby inhibiting their toxic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Ataxin 2 expression is reduced using antisense compounds, then neurodegenerative disease symptoms are improved, but the complexity of treatment protocols increases
Solution Approach 1:
The patent modifies the chemical structure of oligonucleotides by changing parameters such as sugar modifications (2'-O-methoxyethyl, 2'-fluoro), phosphorothioate linkages, and cap structures to optimize binding affinity and stability against nucleases, thereby improving treatment effectiveness while maintaining manageable protocol complexity
Solution Approach 2:
The invention uses composite oligonucleotide structures combining multiple modifications (backbone modifications, sugar modifications, base modifications) to create molecules that simultaneously achieve high binding affinity, nuclease resistance, and cellular uptake efficiency
2Object-affected harmful factors
If modified oligonucleotides are used to target Ataxin 2, then protein toxicity is reduced, but manufacturing complexity increases
Solution Approach 1:
The oligonucleotide molecule is segmented into functional regions with specific modifications: 5' cap structure for stability, phosphorothioate backbone for nuclease resistance, and specific base sequences for target binding, allowing each segment to be optimized independently
Solution Approach 2:
The patent employs intermediary chemical modifications such as 2'-O-methoxyethyl and 2'-fluoro groups that serve as mediators to enhance the oligonucleotide's binding affinity and stability without directly increasing manufacturing complexity
3Duration of action of moving object
If antisense compounds are administered to reduce Ataxin 2 mRNA, then disease progression is halted, but the time required for therapeutic effect increases
Solution Approach 1:
The oligonucleotides are pre-modified with stabilizing caps and phosphorothioate linkages before administration, enabling them to immediately begin binding to Ataxin 2 mRNA and preventing its translation, thereby reducing the time to therapeutic effect while ensuring sustained action
Solution Approach 2:
The patent designs oligonucleotides with continuous binding capability through phosphorothioate backbones and sugar modifications that maintain stable hybridization to the target mRNA, ensuring continuous inhibition of Ataxin 2 protein production without interruption
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Reduction of Ataxin 2 mRNA and protein levels effectively treats, prevents, or ameliorates neurodegenerative diseases by targeting Ataxin 2, providing therapeutic benefits for conditions like SCA2, ALS, and parkinsonism.
Implementation Method 1
compounds useful for modulating expression of Ataxin 2 mRNA and protein are antisense compounds
Data Source
AI summary
Disclosed herein are antisense compounds and methods for decreasing Ataxin 2 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotropic sclerosis (ALS), and parkinsonism.